Biodegradable drug delivery systems for the sustained release of proteins
Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.
1. A method for making a biodegradable intraocular implant that provides continuous release of a protein in a biologically active form for at least 90 days after placement of the implant in an eye of a mammal, the method comprising:
a. providing a dry powder comprising one or more proteins and, optionally, one or more excipients, salts, buffering agents, preservatives, polyelectrolytes, or combination thereof;
b. blending the dry powder with at least two poly(D,L-lactide-co-glycolide) copolymers to form a mixture wherein one of the copolymers has an ester end group and the other copolymer has an acid end group;
c. extruding the mixture at a temperature between 60° C. and 90° C. to form a filament;
d. cutting the filament to form an implant 0.5 to 10 mm in length suitable for placement in an ocular region of an eye.
2. The method of claim 1 , wherein the biodegradable intraocular implant effectively treats an ocular condition.
3. The method of claim 2 , wherein the ocular condition is selected from the group consisting of ocular neovascularization, choroidal neovascularization, macular degeneration, and macular edema.
4. The method of claim 1 , wherein the protein is an antibody, antibody fragment, DARPin, or anticalin that binds vascular endothelial growth factor (VEGF) or platelet-derived growth factor (PDGF).